SAT0044 HIGH THERAPEUTIC EFFICACY OF ORAL RAS INHIBITORS IN COLLAGEN INDUCED ARTHRITIS: INHIBITION OF RELEVANT MAP-KINASES AND THE CONSEQUENT INDUCTION OF AUTOREACTIVE PATHOGENIC T CELLS AND AUTOANTIBODIES. (June 2019)

• Record Type: Journal Article
• Authors: Zayoud, Morad; Barshack, Iris; Vax, Einav; Goldstein, Itamar
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1085
• Page End: 1086
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.4548
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The Ras family of GTPases plays an important role in signaling nodes downstream to T cell antigen receptor (TCR) and CD28, potentially lowering the threshold for TCR activation by autoantigens [1]. Somatic mutation in NRAS or KRAS may cause a rare autoimmune disorder coupled with abnormal expansion of lymphocytes. T cells from Rheumatoid Arthritis (RA) patients show excessive activation of Ras/MEK/ERK pathway. The small molecule Farnesylthiosalicylic acid (FTS) interferes with the interaction between RasGTPases and their prenyl-binding chaperones to inhibit proper plasma membrane localization and effective downstream signaling. Previous studies in the Lewis rat adjuvant induced arthritis show that FTS attenuates arthritis development and that the inhibition of pathogenic Th17-type cells is a central mechanism of action of this compound [2]. Objectives: To further study the therapeutic efficacy and molecular mechanisms that mediate the immunomodulatory effects of FTS in DBA/1 mouse collagen type-II induced arthritis (CIA) the pre-clinical model. Methods: Arthritis was induced in 8-10 week old male DBA/1 mice by immunization with collagen type-II (CII) and complete Freund's adjuvant. Animals were treated semi-prophylactically with daily oral FTS (100 mg/kg); weekly i.p. injection of MTX (0.5 mg/kg); or daily 0.5% CMC vehicle solution (control treatment). Arthritis severity was graded daily by a validated clinical score (0-16 scale), starting at disease onset till study termination. In addition, multiple relevant immunological and molecular biomarkers were analyzed. Results: We found that the clinical scores of mice in the FTS and MTX arms was significantly reduced (by ∼80%, area under curve) compared to the control arm. Accordingly, FTS therapy significantly reduced joint pathology scores for inflammation, pannus formation, bone resorption, and cartilage damage. FTS also significantly inhibited the production of pathogenic anti-CII autoantibodies, anti–citrullinated peptide antibodies, and notably the de-sialylation of these autoantibodies as compared to control mice (Figure 1 ). The analysis of the effect of FTS on the T cell response to CII immunization, revealed strong attenuation of IL-22, IL-17, IL-9, GM-CSF, TNF, and IFN-gamma producing pro-inflammatory CD4+ Th cells. Importantly, we found that in vitro FTS treatment during TCR-stimulation (anti-CD3/CD28 mAbs) significantly inhibited the ensuing phosphorylation of multiple critical MAP kinases such as Erk, Akt, p38, and mTOR. Conclusion: We determined in the preclinical CIA model that FTS, a first-in-class oral Ras-GTPases inhibitor, is a potent immune modulator, via the inhibition of TCR/CD28/Ras-dependent activation of critical MAPKs, consequently attenuating the generation of pro-inflammatory autoreactive T cells. References: [1] Singh K, et al. (2012) K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis. Proc Natl Acad Sci USA109(25):E1629-1637. [2] Zayoud M, et al. (2017) Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. Frontiers in immunology8:799. Acknowledgement: This work was supported by the U.S Department of Defense Grant number AMRMC W81XWH-14-1-0609/10 Disclosure of Interests: None declared